Cumberland Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2015
Filed with the SEC on Mar 14, 2016 and accepted by EDGAR at Mar 14, 2016, 17:24 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-10-01 to 2015-12-31 | $8.0m | us-gaap:SalesRevenueNet |
| Revenue | 12 months2015-01-01 to 2015-12-31 | $900.0k | us-gaap:Revenues |
| Cost of revenue | 12 months2015-01-01 to 2015-12-31 | $5.0m | us-gaap:CostOfGoodsSold |
| Research and development | 12 months2015-01-01 to 2015-12-31 | $3.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-10-01 to 2015-12-31 | $162.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2015-01-01 to 2015-12-31 | $1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2015-01-01 to 2015-12-31 | $73.9k | us-gaap:InterestExpense |
| Income tax | 12 months2015-01-01 to 2015-12-31 | $575.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-10-01 to 2015-12-31 | $151.1k | us-gaap:NetIncomeLoss |
| Net income | 12 months2015-01-01 to 2015-12-31 | $731.4k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-10-01 to 2015-12-31 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2015-01-01 to 2015-12-31 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-10-01 to 2015-12-31 | $0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2015-01-01 to 2015-12-31 | $0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2015-01-01 to 2015-12-31 | 17,094,754 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2015-01-01 to 2015-12-31 | $5.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2015-01-01 to 2015-12-31 | $143.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2015-01-01 to 2015-12-31 | $5.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2015-12-31 | $38.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-12-31 | $67.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-12-31 | $91.9m | us-gaap:Assets |
| Current liabilities | At period end2015-12-31 | $12.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-12-31 | $15.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-12-31 | $76.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-16-012682. Last ingested by Listed: Nov 11, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.